Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPRF | P10586 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21872040 | 1.00 | PTPN1 (0.36) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL21872204 | 1.00 | PTPN1 (0.36) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL21793213 | 0.90 | — | — | |
| SCHEMBL24164200 | 0.77 | — | — | |
| SCHEMBL29230098 | 0.73 | — | — | |
| SCHEMBL8127649 | 0.72 | HPGD (0.42) | — | |
| SCHEMBL11520116 | 0.72 | KIF11 (0.36) | — | |
| SCHEMBL11695775 | 0.71 | METAP2 (0.31) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL16534025 | 0.70 | BACE1 (0.34) | PTPN1 | |
| SCHEMBL2624390 | 0.69 | CCNE1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | disclosed |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | PTPN1 3748/4885PTPRC 4069/4885PTPRF 3635/4885 |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | PTPN1 4244/4885PTPRC 3733/4885PTPRF 2773/4885 |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | PTPN1 4800/4885PTPRC 4176/4885PTPRF 3733/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | PTPN1 3324/4885PTPRC 3846/4885PTPRF 2345/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | PTPN1 4800/4885PTPRC 4176/4885PTPRF 3733/4885 |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | PTPN1 895/4885PTPRC 2815/4885PTPRF 2246/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | PTPN1 4800/4885PTPRC 4176/4885PTPRF 3733/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | PTPN1 4244/4885PTPRC 3733/4885PTPRF 2773/4885 |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | PTPN1 3291/4885PTPRC 3260/4885PTPRF 1807/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | PTPN1 3238/4885PTPRC 3261/4885PTPRF 1847/4885 |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | PTPN1 3302/4885PTPRC 3293/4885PTPRF 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.